BRAF and neoplasm: RAS and several of its downstream effectors, including BRAF, have since been shown to be commonly mutated in broad range of human cancers and biological studies have confirmed that RAS pathway activation promotes tumor initiation, progression and metastatic spread in many contexts [28].